New drug tested to tame dangerous antibodies in blood clot disorder

This study tested if adding a drug called Telitacicept to standard treatment could help control harmful antibody levels in adults with a high-risk type of Antiphospholipid Syndrome (APS), a condition that causes abnormal blood clotting. Twenty patients were randomly assigned to receive either standard care plus weekly Telitacicept injections or standard care alone for 48 weeks. The main goal was to see if the drug could lower the levels of these problematic antibodies.